drugset / Trial / NCT00262210

A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers

NCT00262210

Phase 2 Completed 50 enrolled National Health Research Institutes, Taiwan
RandomizedParallel-groupOpen-labelTreatment

Summary

\* AIMS OF THE STUDY 1. To test if steroid-free chemotherapeutic regimens decrease the risk of HBV reactivation and hepatitis development in HBsAg (+) carriers. 2. To compare the efficacy of steroid-free chemotherapeutic regimens with that of steroid-containing regimens in terms of lymphoma control. 3. To study the change of activity of HBV and other hepatotropic viruses during the course of chemotherapy.

Timeline

Start
1995-06
Primary completion
Completion
1999-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 187.5 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 650 mg/m2 Intravenous
Subject Epirubicin Small molecule 20 mg/m2 Intravenous
Subject Epirubicin Small molecule 60 mg/m2 Intravenous
Subject Etoposide Small molecule 55 mg/m2 Intravenous
Subject Etoposide Small molecule 60 mg/m2 Intravenous
Subject Prednisolone Other / unclassified 60 mg/m2 Oral

Indications